Drug Trial Radar · NCT04440592
Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis
Last checked: Nov 20, 2026Latest source record: Dec 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
76
Actual
Start
Feb 5, 2021
Primary completion
Jan 17, 2024
Study completion Feb 14, 2024
Sponsor
- Lead sponsor
- Tanabe Pharma America, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy of MT-7117 treatment in subjects with diffuse cutaneous systemic sclerosis (dcSSc) using the American College of Rheumatology Composite Response Index in Diffuse Systemic Sclerosis (ACR CRISS) at Week 52
Conditions
- Diffuse Cutaneous Systemic Sclerosis
Interventions
MT-7117Drug
MT-7117
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The ACR CRISS Composite Score (0-1) at Week 52Time frame: Week 52
Locations
34 sites in 8 countries. Site status is shown where the registry gives one.
Arizona Arthritis
Glendale, Arizona
Pacific Arthritis Care Center
Los Angeles, California
The Board of Trustees of the Leland Stanford Junior University
Redwood City, California
Yale School of Medicine - The Anlyan Center (TAC) for Medical Research & Education
New Haven, Connecticut
GNP Research
Hollywood, Florida
Millennium Research
Ormond Beach, Florida
Johns Hopkins University
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan
Shelby Research, LLC
Memphis, Tennessee
The University of Texas Medical School at Houston
Houston, Texas
Universitair Ziekenhuis Gent
Ghent, Belgium
Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman
Liège, Belgium
UZ Leuven
Leuven, Vlaam Gewest, Belgium
Mount Sinai Hospital, The Rebecca Macdonald Centre For Arthritis And Autoimmune Disease
Toronto, Ontario, Canada
Internistisches Zentrum des Universitaetsklinikums Erlangen
Erlangen, Germany
University Hospital Of Tuebingen
Tübingen, Baden-Wuettemberg, Germany
CIRI, Centrum fur innovative Diagnostik und Therapie Rheumatologie und Immunologie (GmbH) Am Klinikum der Johann Wolfgang Goethe-Universitat
Frankfurt am Main, Hesse, Germany
University of Ferrara Azienda Ospedaliero-Universitaria Sant' Anna
Cona, Ferrera, Italy
Universita degli Studi di Milano - Azienda Ospedaliera Istituto Ortopedico Gaetano Pini
Milan, Lombardy, Italy
Uniwersytecki Szpital Kliniczny w Bialymstoku
Bialystok, Poland
Centrum Kliniczno-Badawcze J.Brzezicki, B.Gornikiewicz-Brzezicka Lekarze Spolka partnerska
Elblag, Poland
Malopolskie Centrum Kliniczne
Krakow, Poland
Centrum Medyczne Plejady
Krakow, Poland
Medyczne Centrum Hetmanska
Poznan, Poland
Medycyna Kliniczna
Warsaw, Poland
Centrum Medyczne Oporow
Wroclaw, Poland
Hospital Del Mar
Barcelona, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Regional Universitario de Málaga
Málaga, Spain
Institut d'Investigacio i Innovacio Parc Tauli, Hospital Universitari Parc Taulí
Sabadell, Barcelona, Spain
Western General Hospital
Edinburgh, United Kingdom
The Royal Free Hospital - Royal Free London NHS Foundation Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.